PVT1 and cancer: First, genomic alteration of PVT1 was analyzed using the TCGA dataset across multiple cancer types; we found that ESCA was the second-ranking cancer type with high PVT1 alterations with 20% PVT1 amplification and around 75% of ESCA cases contained both amplification and duplications (> 3 N) (Fig. 1a).